Modernizing clinical trial eligibility criteria: Recommendations of the American society of clinical oncology-friends of cancer research brain metastases working group

Journal of Clinical Oncology

Volumn 35, Issue 33, 2017, Pages 3760-3773

  Lin, Nancy U ^a   Prowell, Tatiana ^c,d   Tan, Antoinette R ^e   Kozak, Marina ^f   Rosen, Oliver ^b   Amiri Kordestani, Laleh ^c   White, Julia ^h   Sul, Joohee ^c   Perkins, Louise ^g   Beal, Katherine ⁱ   Gaynor, Richard ^j   Kim, Edward S ^e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Deciphera Pharmaceuticals LLC   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e LEVINE CANCER INSTITUTE   (United States)

^f Friends of Cancer Research   (United States)

^g Melanoma Research Alliance   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j ELI LILLY AND COMPANY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGE; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RESEARCH; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; EXPERIMENTAL THERAPY; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL SOCIETY; MENINGEAL METASTASIS; MULTIPLE ORGAN FAILURE; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TELECONFERENCE; WORKSHOP; BRAIN TUMOR; METASTASIS; ORGANIZATION AND MANAGEMENT; PROCEDURES; SECONDARY; UNITED STATES;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; ELIGIBILITY DETERMINATION; HUMANS; NEOPLASM METASTASIS; UNITED STATES;

EID: 85034452082     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.74.0761     Document Type: Article

References (73)

1. Kim ES, Bernstein D, Hilsenbeck SG, et al: Modernizing eligibility criteria for molecularly driven trials. J Clin Oncol 33:2815-2820, 2015
2. McCoach CE, Berge EM, Lu X, et al: A brief report of the status of central nervous system metastasis enrollment criteria for advanced non-small cell lung cancer clinical trials: A review of the ClinicalTrials. gov trial registry. J Thorac Oncol 11: 407-413, 2016
3. Davis FG, Dolecek TA, McCarthy BJ, et al: Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro-oncol 14: 1171-1177, 2012
4. American Cancer Society. Cancer Facts & Figures. Atlanta, GA, American Cancer Society, 2007
5. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66:7-30, 2016
6. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22: 2865-2872, 2004
7. Costa DB, Shaw AT, Ou SH, et al: Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33:1881-1888, 2015
8. Ou SH, Ahn JS, De Petris L, et al: Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: A phase II global study. J Clin Oncol 34:661-668, 2016
9. Gadgeel SM, Shaw AT, Govindan R, et al: Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive nonsmall-cell lung cancer. J Clin Oncol 34:4079-4085, 2016
10. Pestalozzi BC, Holmes E, de Azambuja E, et al: CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: A retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol 14:244-248, 2013
11. Lin NU, Claus E, Sohl J, et al: Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases. Cancer 113:2638-2645, 2008
12. Kennecke H, Yerushalmi R, Woods R, et al: Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271-3277, 2010
13. Lin NU, Vanderplas A, Hughes ME, et al: Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118:5463-5472, 2012
14. Wen PY, Schiff D, Cloughesy TF, et al: It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol 29:3211-3213, 2011
15. Gounder MM, Nayak L, Sahebjam S, et al: Evaluation of the safety and benefit of phase I oncology trials for patients with primary CNS tumors. J Clin Oncol 33:3186-3192, 2015
16. U.S. Department of Health and Human Services: Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER): Guidance for industry: Expedited programs for serious conditions - drugs and biologics. https://www.fda.gov/ downloads/drugs/guidancecomplianceregulatory information/guidances/ucm358301.pdf
17. Beaver JA, Ison G, Pazdur R: Reevaluating eligibility criteria - balancing patient protection and participation in oncology trials. N Engl J Med 376: 1504-1505, 2017
18. Peters S, Camidge DR, Shaw AT, et al: Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377: 829-838, 2017
19. Lin NU, Diéras V, Paul D, et al: Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452-1459, 2009
20. Lin NU, Carey LA, LiuMC, et al: Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26:1993-1999, 2008
21. Morikawa A, Peereboom DM, Thorsheim HR, et al: Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: A prospective study. Neuro-oncol 17:289-295, 2015
22. Gril B, Palmieri D, Bronder JL, et al: Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 100: 1092-1103, 2008
23. Lockman PR, Mittapalli RK, Taskar KS, et al: Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16: 5664-5678, 2010
24. Ni J, Ramkissoon SH, Xie S, et al: Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med 22:723-726, 2016
25. Lin NU: Targeted therapies in brain metastases. Curr Treat Options Neurol 16:276, 2014
26. Tsimberidou AM, Letourneau K, Wen S, et al: Phase I clinical trial outcomes in 93 patients with brain metastases: The MD Anderson Cancer Center experience. Clin Cancer Res 17:4110-4118, 2011
27. Krop IE, Lin NU, Blackwell K, et al: Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: A retrospective, exploratory analysis in EMILIA. Ann Oncol 26:113-119, 2015
28. Besse B, Lasserre SF, Compton P, et al: Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16:269-278, 2010
29. Gore ME, Hariharan S, Porta C, et al: Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 117:501-509, 2011
30. Cohen JV, Alomari AK, Vortmeyer AO, et al: Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. Cancer Immunol Res 4: 179-182, 2016
31. Margolin K, Ernstoff MS, Hamid O, et al: Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol 13:459-465, 2012
32. Ahmed KA, Stallworth DG, Kim Y, et al: Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 27:434-441, 2016
33. Tawbi HA-H, Forsyth PAJ, Algazi AP, et al: Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. J Clin Oncol 35 (suppl; abstr 9507), 2017
34. Long GV, Atkinson V, Menzies AM, et al: A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). J Clin Oncol 35 (suppl; abstr 9508), 2017
35. Falchook GS, Long GV, Kurzrock R, et al: Dabrafenib in patients with melanoma, untreated brainmetastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 379:1893-1901, 2012
36. Bachelot T, Romieu G, Campone M, et al: Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study. Lancet Oncol 14:64-71, 2013
37. Cortés J, Dieras V, Ro J, et al: Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial. Lancet Oncol 16:1700-1710, 2015
38. Wu YL, Zhou C, Cheng Y, et al: Erlotinib as second-line treatment in patients with advanced nonsmall-cell lung cancer and asymptomatic brain metastases: A phase II study (CTONG-0803). Ann Oncol 24:993-999, 2013
39. Toyokawa G, Seto T, Takenoyama M, et al: Insights into brain metastasis in patients with ALK+ lung cancer: Is the brain truly a sanctuary?. Cancer Metastasis Rev 34:797-805, 2015
40. Nayak L, DeAngelis L, Wen P, et al: The Neurologic Assessment in Neuro-Oncology (NANO) scale: A tool to assess neurologic function for integration in the Radiologic Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol 19: 625-635, 2017
41. Osoba D, Aaronson NK, Muller M, et al: The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5:139-150, 1996
42. Taphoorn MJ, Claassens L, Aaronson NK, et al: EORTC Quality of Life Group, and Brain Cancer, NCIC and Radiotherapy Groups: An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer 46:1033-1040, 2010
43. Armstrong TS, Gning I, Mendoza TR, et al: Clinical utility of the MDASI-BT in patients with brain metastases. J Pain Symptom Manage 37:331-340, 2009
44. Glantz MJ, Cole BF, Forsyth PA, et al: Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54:1886-1893, 2000
45. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
46. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
47. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
48. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990
49. Lin NU, Lee EQ, Aoyama H, et al: Response Assessment in Neuro-Oncology (RANO) group: Challenges relating to solid tumour brain metastases in clinical trials, part 1: Patient population, response, and progression. A report from the RANO group. Lancet Oncol 14:e396-e406, 2013
50. Lin NU, Lee EQ, Aoyama H, et al: Response Assessment in Neuro-Oncology (RANO) group: Response assessment criteria for brain metastases: Proposal from the RANO group. Lancet Oncol 16: E270-e278, 2015
51. Di Giacomo AM, Margolin K: Immune checkpoint blockade in patients with melanoma metastatic to the brain. Semin Oncol 42:459-465, 2015
52. Shi W, Dicker AP: CNS metastases in patients with non-small-cell lung cancer and ALK gene rearrangement. J Clin Oncol 34:107-109, 2016
53. Cairncross JG, Kim JH, Posner JB: Radiation therapy for brain metastases. Ann Neurol 7:529-541, 1980
54. Gaspar L, Scott C, Rotman M, et al: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745-751, 1997
55. Sperduto PW, Kased N, Roberge D, et al: Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419-425, 2012
56. Johung KL, Yeh N, Desai NB, et al: Extended survival and prognostic factors for patients with ALKrearranged non-small-cell lung cancer and brain metastasis. J Clin Oncol 34:123-129, 2016
57. Dyer MA, Kelly PJ, Chen YH, et al: Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases. Int J Radiat Oncol Biol Phys 83: E479-e486, 2012
58. Yang TJ, Oh JH, Folkert MR, et al: Outcomes and prognostic factors in women with 1 to 3 breast cancer brain metastases treated with definitive stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 90:518-525, 2014
59. Aoyama H, Shirato H, Tago M, et al: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 295:2483-2491, 2006
60. Kocher M, Soffietti R, Abacioglu U, et al: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol 29:134-141, 2011
61. Freedman RA, Gelman RS, Wefel JS, et al: Translational Breast Cancer Research Consortium (TBCRC) 022: A phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol 34:945-952, 2016
62. Shaw AT, Gandhi L, Gadgeel S, et al: Study Investigators: Alectinib in ALK-positive, crizotinibresistant, non-small-cell lung cancer: A singlegroup, multicentre, phase 2 trial. Lancet Oncol 17: 234-242, 2016
63. Gainor JF, Sherman CA, Willoughby K, et al: Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 10:232-236, 2015
64. Ou SH, Sommers KR, Azada MC, et al: Alectinib induces a durable (.15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist 20: 224-226, 2015
65. Mack F, Baumert BG, Schäfer N, et al: Therapy of leptomeningeal metastasis in solid tumors. Cancer Treat Rev 43:83-91, 2016
66. Balm M, Hammack J: Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 53:626-632, 1996
67. Chamberlain M, Soffietti R, Raizer J, et al: Leptomeningeal metastasis: A Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro-oncol 16:1176-1185, 2014
68. Chamberlain MC: Leptomeningeal metastasis. Curr Opin Oncol 22:627-635, 2010
69. Chamberlain M, Junck L, Brandsma D, et al: Leptomeningeal metastases: A RANO proposal for response criteria. Neuro-Oncol 19:484-492, 2016
70. Floudas CS, Chandra AB, Xu Y: Vemurafenib in leptomeningeal carcinomatosis from melanoma: A case report of near-complete response and prolonged survival. Melanoma Res 26:312-315, 2016
71. Clarke JL, Pao W, Wu N, et al: High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningealmetastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99:283-286, 2010
72. Cardoso F, Costa A, Norton L, et al: European School of Oncology; European Society of Medical Oncology: ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 23:489-502, 2014
73. Ramakrishna N, Temin S, Chandarlapaty S, et al: Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:2100-2108, 2014